Altria Abandons Option to Buy Additional Cronos Shares.

Dec.20.2022

Altria Group cancels option to buy additional shares in Cronos Group, resulting in a $483 million capital loss.

According to a press release from Altria, the company has notified Cronos Group that it has irrevocably relinquished its options to purchase additional common shares of Cronos, as well as any ownership rights or common shares underlying those options, without any consideration.

In March 2019, Altria, through its subsidiary, acquired a 45% stake and stock warrants in Cronos. The warrants can be exercised before March 8, 2023, at a price of CAD 19 (USD 13.93) per share. Prior to abandoning the warrants, Altria's subsidiary held 156,573,537 common shares of Cronos (approximately 41% of the issued and outstanding common shares), and through full exercise of the warrants, could increase its ownership to 240,816,760 common shares of Cronos (approximately 52% of the issued and outstanding common shares after full exercise of the warrants).

On December 15th, 2022, the closing price for Cronos common shares was $3.81 CAD ($2.79 USD), and for the past 12 months, the trading price for Cronos common shares has not exceeded $6 CAD ($4.39 USD). Considering Cronos' trading level and the expiration of its warrants in March 2023, on December 16th, 2022, Altria decided to forfeit its warrants. As a result of forfeiting the warrants, Altria expects to claim a capital loss of $483 million USD in its 2022 federal merger asset tax return. Altria will continue to hold 156,573,537 shares of Cronos common stock.

Tobacco company Altria holds common stock in Cronos through its subsidiary for investment purposes. Altria will continue to assess Cronos' business and prospects, as well as all other relevant factors, to determine whether it or its affiliates will dispose of such shares on the open market through private negotiation transactions (possibly involving Cronos or third parties) or through other means.

#Asia #Open system e-cigarettes #Japan #Regulation #Altria

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

California Federal Judge Signals Likely Class Certification in Juul–Altria Antitrust Case

U.S. District Judge William Orrick of the Northern District of California indicated on Friday that he will likely certify classes of direct and indirect purchasers accusing e-cigarette makers Juul Labs Inc. and former rival Altria Group Inc. of conspiring to limit product variety and violate antitrust laws.

Oct.20 by 2FIRSTS.ai

Product | OXVA launches Artio 2 liquid-tobacco pod device, positioned as distinct from HNB and traditional flavored e-cigarettes

OXVA has released its Artio 2 pod device featuring the Liquid Tobacco Intelligent (LTI) platform. It offers around 400 puffs per charge, pods equivalent to about 35 cigarettes, five tobacco and shisha flavors, and a 900mAh battery with 30-minute fast charging. The company positions the device as distinct from HNB and traditional flavored e-cigarettes.

Nov.27 by 2FIRSTS.ai

2Firsts Interview with IBVTA: UK Vape Tax May Weaken Harm Reduction Efforts

As the UK prepares to introduce its first-ever vape tax in 2026, questions are growing about how the measure will reshape the country’s harm reduction landscape. IBVTA tells 2Firsts that while it was not in favour of the new duty, it accepts that it is being implemented and is working with regulators to ensure a smooth rollout — warning, however, that higher costs could slow smokers’ transition to safer alternatives.

Oct.07

CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches

CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.

Nov.04